Gene Correction of LGMD2A Patient-Specific iPSCs for the Development of Targeted Autologous Cell Therapy

Sridhar Selvaraj, Neha R. Dhoke, James Kiley, Alba Judith Mateos-Aierdi, Sudheer Tungtur, Ricardo Mondragon-Gonzalez, Grace Killeen, Vanessa K.P. Oliveira, Adolfo López de Munain, Rita C.R. Perlingeiro

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Limb girdle muscular dystrophy type 2A (LGMD2A), caused by mutations in the Calpain 3 (CAPN3) gene, is an incurable autosomal recessive disorder that results in muscle wasting and loss of ambulation. To test the feasibility of an autologous induced pluripotent stem cell (iPSC)-based therapy for LGMD2A, here we applied CRISPR-Cas9-mediated genome editing to iPSCs from three LGMD2A patients to enable correction of mutations in the CAPN3 gene. Using a gene knockin approach, we genome edited iPSCs carrying three different CAPN3 mutations, and we demonstrated the rescue of CAPN3 protein in myotube derivatives in vitro. Transplantation of gene-corrected LGMD2A myogenic progenitors in a novel mouse model combining immunodeficiency and a lack of CAPN3 resulted in muscle engraftment and rescue of the CAPN3 mRNA. Thus, we provide here proof of concept for the integration of genome editing and iPSC technologies to develop a novel autologous cell therapy for LGMD2A.

Original languageEnglish (US)
Pages (from-to)2147-2157
Number of pages11
JournalMolecular Therapy
Volume27
Issue number12
DOIs
StatePublished - Dec 4 2019

Keywords

  • CAPN3
  • Calpain 3
  • autologous cell therapy
  • gene correction
  • genome editing
  • iPSCs
  • induced pluripotent stem cells
  • limb girdle muscular dystrophy type 2A
  • myogenic progenitors

PubMed: MeSH publication types

  • Journal Article
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

Fingerprint Dive into the research topics of 'Gene Correction of LGMD2A Patient-Specific iPSCs for the Development of Targeted Autologous Cell Therapy'. Together they form a unique fingerprint.

  • Cite this

    Selvaraj, S., Dhoke, N. R., Kiley, J., Mateos-Aierdi, A. J., Tungtur, S., Mondragon-Gonzalez, R., Killeen, G., Oliveira, V. K. P., López de Munain, A., & Perlingeiro, R. C. R. (2019). Gene Correction of LGMD2A Patient-Specific iPSCs for the Development of Targeted Autologous Cell Therapy. Molecular Therapy, 27(12), 2147-2157. https://doi.org/10.1016/j.ymthe.2019.08.011